First Line Trials

1. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab, Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small cell Lung Cancer (NSCLC) (CheckMate 012) 
 
          ClinicalTrials.gov Identifier:                   NCT01454102         

This study is currently active but not recruiting.
 
The study is evaluating the safety and tolerability of Nivolumab as monotherapy among subjects with untreated, asymptomatic brain metastases and no evidence of cerebral edema.

Ontario
Local Institution
Hamilton, Ontario, Canada, L8V 5C2
 
Local Institution
Ottawa, Ontario, Canada, K1H 8L6
 
Local Institution
Toronto, Ontario, Canada, M5G 2M9

2. A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

         ClinicalTrials.gov Identifier:                  NCT02185690        

This study is currently active but not recruiting.

MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations. These data suggest that MEK162 may provide a potential benefit in cancer indications harboring these mutations. MEK162 is currently being investigated in phase I clinical testing and has been well tolerated up to an MTD of 45mg BID in cancer patients. 

Alberta
Cross Cancer Institute 
Edmonton, Alberta, T6G1Z2

Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
 
The Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada, K1G 3Y9
 
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G2M9

3. Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

      ClinicalTrials.gov Identifier:               NCT02186847     

This study is currently active but not recruiting.
 
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Metformin hydrochloride may shrink tumors and keep them from coming back. It is not yet known whether chemotherapy and radiation therapy is more effective when given with or without metformin hydrochloride in treating stage III non-small cell lung cancer. 

Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
 
Saskatchewan
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
 
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4
4. A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
 
        ClinicalTrials.gov Identifier:                 NCT02367794        

This study is currently active but not recruiting. 

This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naïve patients with Stage IV squamous non-small cell lung cancer (NSCLC).

Ontario
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada, L4M 6M2
 
William Osler Health Centre
Etobicoke, Ontario, Canada, M9V 1R8
 
Lakeridge Health Center
Oshawa, Ontario, Canada, L1J 2J2
 
Quebec
Cite de La Sante de Laval; Hemato-Oncologie
Laval, Quebec, Canada, H7M 3L9
 
Hôpital Maisonneuve - Rosemont
Montreal, Quebec, Canada, H1T 2M4
 
Hôpital du Sacré-Coeur de Montreal
Montreal, Quebec, Canada, H4J 1C5
 
St-Jerome Medical Research Inc
St. Jerome, Quebec, Canada, J7Z 5T3

5. A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]

      ClinicalTrials.gov Identifier:              NCT02366143      

This study is currently active but not recruiting.
 
This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin and paclitaxel with or without bevacizumab compared with treatment with carboplatin plus (+) paclitaxel and bevacizumab in chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

Ontario
Lakeridge Health Center
Oshawa, Ontario, Canada, L1J 2J2

6.  An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

       ClinicalTrials.gov Identifier:              NCT02477826      

This study is not currently recruiting participants in Canada. 
 
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC). The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer.
 
Alberta
Cross Cancer Institute                                                               
Edmonton, Alberta, Canada, T6G 1Z2
 
Newfoundland and Labrador                         
Dr. H.Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
 
Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
 
Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
 
CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski
Rimouski, Quebec, Canada, G5L 5T1
 
Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
 
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec
Trois-Rivieres, Quebec, Canada, G8Z 3R9
 
CHU de Quebec - Universite Laval
Quebec, Canada, G1R 2J6
 
Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval
Quebec, Canada, G1V 4G5

7. Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC)

          ClinicalTrials.gov Identifier:                    NCT02453282        

This study is active but not currently recruiting. 
 
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.

Ontario 
Research Site
Kingston, Ontario, Canada, K7L 2V7
 
Research Site
Newmarket, Ontario, Canada, L3Y 2P9
 
Research Site
Oshawa, Ontario, Canada, L1G 2B9
 
Research Site
Sault Ste. Marie, Ontario, Canada, P6A 0A8
 
Research Site
St. Catharines, Ontario, Canada, L2S 0A9
 
Research Site
Sudbury, Ontario, Canada, P3E 5J1
 
Research Site
Toronto, Ontario, Canada, M5G 2M9
 
Saskatchewan
Research Site
Regina, Saskatchewan, Canada, S4T 7T1
 
Research Site
Saskatoon, Saskatchewan, Canada, S7N 4H4

8. A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

         ClinicalTrials.gov Identifier:                    NCT02411448          

This study is active but not currently recruiting.
 
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer.

Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2

9. Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

           ClinicalTrials.gov Identifier:                    NCT02576574        

This study is active but not currently recruiting.

The purpose of this study is to demonstrate superiority with regard to progression free survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumours.

New Brunswick 
The Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8

Ontario
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5

10. Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)

 
            ClinicalTrials.gov Identifer:                        NCT02659059         
 
This study is active but not currently recruiting. 
 
 
The purpose of this study is to determine the objective response rate (ORR) in PD-L1+ stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

Ontario 
Kingston Regional Cancer Centre
Kingston, Ontario, Canada, K7L 2V7
 
Sault Area Hospital
Sault Ste Marie, Ontario, Canada, P6B 0A8
 

Quebec
Csss De St-Jerome 
St. Jerome, Quebec, Canada, J7Z 5T3


11. A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer(NSCLC) (B-FAST)

         ClinicalTrials.gov Identifier:                    NCT03178552         

This study is currently recruiting participants. 

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Alberta
Cross Cancer Institute, Edmonton                                                                           Recruiting

Ontario 
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials       Recruiting
Barrie, Ontario, Canada, L4M 6M2
 
William Osler Health System Brampton Civic Hospital       Recruiting
Brampton, Ontario, Canada, L6R 3J7
 
London Health Sciences Centre · Victoria Hospital; Department of Medicine       Active, not recruiting
London, Ontario, Canada, N6A 5W9
 
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center       Recruiting
Oshawa, Ontario, Canada, L1G 2B9
 
Sunnybrook Health Sciences Centre        Recruiting
Toronto, Ontario, Canada, M4N 3M5
 
Princess Margaret Hospital; Medical Oncology Dept       Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
Jewish General Hospital; Sir Mortimer B. Davis                                                       Recruiting
Montreal, Quebec, Canada, H2W 1S6
 
IUCPQ (Hôpital Laval)                                                                                              Active, not recruiting
Quebec City, Quebec, Canada, G1V 4G5

Saskatchewan 
Saskatoon Cancer Agency                                                                                       Recruiting
Saskatoon, Saskatchewan, Canada, SK S7N 4H
 
Manitoba 
CancerCare Manitoba; Department of Medical Oncology                                       Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
 

12. A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy (IPSOS)

        ClinicalTrials.gov Identifier:                  NCT03191786        

This study is active but not currently recruiting. 

This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status of 2-3).
 
New Brunswick
Regional health authority A vitalite health network  
Moncton, New Brunswick, Canada, E1C 8X3
 
Ontario
Ottawa Hospital Research Institute  
Ottawa, Ontario, Canada, K1Y 4E9
 
Sault Area Hospitals  
Sault Ste Marie, Ontario, Canada, P6A 2C4
 
Princess Margaret Cancer Center  
Toronto, Ontario, Canada, M5G 1Z5
 
Quebec
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology        
Montreal, Quebec, Canada, H3T 1E2
 

13. Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)​

        ClinicalTrials.gov Identifier:                     NCT03515837          

This study is active but not currently recruiting. 
 
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.

The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS.

Ontario
William Osler Health System ( Site 0100)
Brampton, Ontario, Canada, L6R 3J7
 
Sunnybrook Health Sciences, Odette Cancer Centre ( Site 0102)
Toronto, Ontario, Canada, M4N 3M5
 
Princess Margaret Cancer Centre ( Site 0104)
Toronto, Ontario, Canada, M5G 2M9

Quebec
Jewish General Hospital ( Site 0105)
Montreal, Quebec, Canada, H3T 1E2

14. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

         ClinicalTrials.gov Identifier:                    NCT03829332          

This study is currently recruiting participants. 
 
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
 
Alberta
Cross Cancer Institute (Site 0400)               Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Study Coordinator, 780-432-8762      
 
Ontario
William Osler Health System (Brampton Civic Hospital) (Site 0402)              Recruiting
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 58389   
  
Windsor Regional Cancer Program (Site 0404)              Recruiting
Windsor, Ontario, Canada, N8W 2X3
Contact: Study Coordinator, 519-253-5253      

British Columbia
Lions Gate Hospital (Site 0407)                                                                     Recruiting
North Vancouver, British Columbia, Canada, V7L 2L7
Contact: Study Coordinator, 604-984-5753 

Quebec
McGill University Health Centre (Site 0418)                                                  Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Study Coordinator, 514-934-1934      

15. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

         ClinicalTrials.gov Identifier:                    NCT03516981        

This study is currently recruiting participants.

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)              Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      

The Ottawa Hospital (Site 0306)                                     Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Study Coordinator, 613-737-7700 x 70175

Princess Margaret Cancer Centre (Site 0309)                  Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Study Coordinator, 416-946-4501
 
Quebec
Jewish General Hospital (Site 0307)              Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674   

CIUSSS du Saguenay-Lac-St-Jean (Site 0305)                 Recruiting
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234
 

16. A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

          ClinicalTrials.gov Identifier:                   NCT03215706         
 
This study is active but not currently recruiting. 
 
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease.
 
Quebec
Local Institution         
Montreal, Quebec, Canada, H1T 2M4
 
Jewish General Hospital         
Montreal, Quebec, Canada, H3T 1E2
 
Mcgill University Health Center - Royal Victoria Hospital         
Montreal, Quebec, Canada, H4A 3J1
 
CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski         
Rimouski, Quebec, Canada, G5L 5T1
 

17. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

         ClinicalTrials.gov Identifier                  NCT02414139        

This study is currently recruiting participants. 

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
 
Nova Scotia
Novartis Investigative Site                               Recruiting
Halifax, Nova Scotia, Canada, B3H 1V7

Ontario
Novartis Investigative Site                               Recruiting
Ottawa, Ontario, Canada, K1H 8L6
 
18. Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
 
         ClinicalTrials.gov Identifier:                    NCT03302234         
 
This study is active but not currently recruiting. 
 
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.
 
Alberta
Tom Baker Cancer Centre (Site 0119)           
Calgary, Alberta, Canada, T2N 4N2
Contact: Study Coordinator, 403-521-3347
     
Manitoba
CancerCare Manitoba (Site 0106)           
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Study Coordinator, 204-787-8776      
 
Quebec
CIUSSS du Saguenay-Lac-St-Jean (Site 0115)           
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234 x 2840
     
CISSS de la Monteregie-Centre (Site 0100)           
Greenfield Park, Quebec, Canada, J4V 2H1
Contact: Study Coordinator, 450-466-5000 x 3226  
    
CISSS-CA Hotel-Dieu de Levis (Site 0108)   
Levis, Quebec, Canada, G6V 3Z1
Contact: Study Coordinator, 418-835-7121 x 3048   
  
CIUSSS Ouest de l'Ile - St-Mary's Hospital (Site 0107)        
Montreal, Quebec, Canada, H3T 1M5
Contact: Study Coordinator, 514-345-3511 x 3981  
    
St-Jerome Medical Research Inc (Site 0113)    
St-Jerome, Quebec, Canada, J7Z 5T3
Contact: Study Coordinator,  450431102042      
 

19. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

         ClinicalTrials.gov Identifier:                 NCT03631199       

This study is active but not curently recruiting. 

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 
Toronto, Ontario, Canada, M5G 1Z6
 
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6

Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2

20. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

        ClinicalTrials.gov Identifier:                  NCT03052608         

This study is currently recruiting participants. 

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population.

Ontario
Princess Margaret Cancer Centre                               Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
McGill University Health Centre                                 Recruiting
Montreal, Quebec, Canada, H4A 3J1